Agency Seeks Public Input on Risk-Based Oversight Approach Across Product Life Cycle. The U.S. Food and Drug Administration is seeking public feedback on the varying risks and other considerations involving generative artificial intelligence-enabled medical devices to inform the agency as it contemplates how to advance a regulatory approach for these evolving products.
First seen on govinfosecurity.com
Jump to article: www.govinfosecurity.com/fda-weighing-possible-regs-for-genai-medical-devices-a-32593
